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Genetic architecture of a disease comprises the number,
frequency, and effect sizes of genetic risk alleles and the
way in which they combine together. Before the genomic
revolution, the only clue to underlying genetic architecture
ofschizophreniacamefromtherecurrenceriskstorelatives
and the segregation patterns within families. From these
clues, very simple genetic architectures could be rejected,
but many architectures were consistent with the observed
family data. The new era of genome-wide association stud-
ies can provide further clues to the genetic architecture of
schizophrenia. We explore models of genetic architecture
by description rather than the mathematics that underpins
them. We conclude that the new genome-wide data allow
us to narrow the boundaries on the models of genetic archi-
tecturethatareconsistentwiththeobserveddata.Agenetic
architecture of many common variants of moderate (rela-
tive risk > approximately 1.2) can be excluded, yet there is
evidence that current generation genome-wide chips do tag
an important proportion of the genetic variation for schizo-
phrenia and that the underlying causal variants will include
common variants of small effect as well as rarer variants of
larger effect. Together, these observations imply that the
total number of genetic variants is very large—of the order
of thousands. The ﬁrst generation of studies have generated
hypotheses that should be testable in the near future and
will further narrow the boundaries on genetic architectures
that are consistent with empirical data.
Keywords:schizophrenia/complexgeneticdisease/genetic
architecture/polygenic
Introduction
Family history is the most important risk factor for
schizophrenia,
1 consistent with a genetic contribution
to its etiology. Traditionally, researchers, eg, McGue
et al,
2,3 and Risch,
4 employed genetic modeling to see
if they could gain insight into the genetic architecture
of schizophrenia. They compared patterns of recurrence
risks for different types of relatives with those expected
under different genetic models. They not only found
that multiple genetic models of genetic architecture
were consistent with observations but also showed that
some simple models could be rejected. The advent of ge-
nome-wide association studies (GWAS) has allowed the
identification of individual genetic risk loci or at least
markers linked to them. This article explores if the
new evidence provided from GWAS provides further
clues to elucidate an understanding of the genetic archi-
tecture of schizophrenia. In doing this, we fully acknowl-
edge the sentiment of the industrial statistician George
Box that ‘‘all models are wrong, but some are useful.’’
Simple models of genetic architecture allow us to devise
hypotheses that can be tested against observable data. A
model is useful until observable data allow it to be
rejected, thereby narrowing the boundaries on models
that remain consistent with observations. In this explora-
tion, we aim to minimize, where possible, the presenta-
tion of detailed mathematical foundations presented
elsewhere (N.R.W. and M.E. Goddard, PhD, unpub-
lished data, 2009).
5
What Is Genetic Architecture?
To a complex trait geneticist, genetic architecture com-
prises 4 factors.
1. Thenumber(n)ofriskallelesthatcontributetodisease
in the population, which could include multiple risk
alleles within a gene.
2. The frequency (qi) in the population of each of the risk
alleles (i = 1 . n), which can be either the major or
minor allele.
3. The effect size of a risk allele that encompasses the
concept of penetrance.
4. Thewayinwhichriskallelesacttogether,additivelyor
with interaction.
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14Both the way in which effect sizes are described and the
way in which we describe the interaction of risk alleles de-
pendonthescaleofmeasurement.Wewillusethetermthe
‘‘risk scale’’ to mean the observed scale of disease. On this
scale, the phenotypic risk is either affected or not affected,
but the genetic risk can be expressed as a probability de-
pendent on the genotype of an individual. On this scale,
effect sizes can be expressed as either the relative risk or
oddsratioofa risk allele for disease.Risk allelesthat com-
bine with interaction (or epistasis) on one scale can com-
bineadditivelyonatransformedscale.Therefore,thesame
genetic architecture can be described as either multiplica-
tive or additive and leads to confusion because the scale of
measurement is often not explicitly stated. Heritability of
schizophrenia is usually described on the ‘‘liability’’ scale;
on this notional scale, risk alleles are usually assumed to
combine additively so that the genetic variance (VG)i s
the sum of the variances contributed by each variant,
6
VG =+
n
i=12qi

1   qi

a2
i ; ½1 
where ai is the effect size of a risk allele, using ‘‘a’’ to empha-
size additive action on this scale. From this equation, we see
that for a given effect size of a risk allele (ie, ai), one with fre-
quency qi = 0.5 will contribute the maximum variance com-
pared with risk variants of higher or lower frequency. Rare
variants (ie, qi close to zero) individually contribute little to
the overall variance because qi(1   qi) is also close to zero.
Infinite combinations of n, qi,a n dai can generate the same
VG. If effect sizes are small or if risk variants are rare, then
thenumberofrisklocimustbelargetoaccountforthegenetic
variance that we know exists from family studies.
The Evidence for a Genetic Etiology of Schizophrenia
Adoption studies
7,8 and recurrence risk to relatives (ta-
ble 1) provide direct evidence for a genetic etiology of
schizophrenia. From disease prevalence (estimated as
0.72%
9 lifetime morbidity risk) and recurrence risks,
we can estimate heritability on the liability scale.
10 Her-
itability is high:A meta-analysis oftwin studies estimated
heritability to be 81% (95% confidence interval (CI) =
73%–90%),
11 and the estimate from a Swedish study
matching >7 million records from the national multigen-
eration database with hospital discharge records was
64.3% (95% CI = 61.7%–67.5%).
12 Other risk factors in-
clude male gender, advanced paternal age, perinatal
events, and recreational drug use (reviewed in Sullivan
1
and Tandon et al
13) . In addition, shared family environ-
menteffectsareestimatedtobesmallbutsignificant;they
explain 11% (95% CI = 3%–19%)
11 and 4.5% (95% CI =
4.4%–7.4%)
12 of the variance in the twin study meta-
analysis and Swedish study, respectively.
Despite the high heritability of schizophrenia, only
a small proportion of cases have a family history of
schizophrenia, reported to be less than one-third
13 and
estimated to be only 3.81% (95% CI = 3.62–4.00) in
the Swedish national study
12 (counting all identified
first-, second-, and third-degree relatives). Genotyping
studies have provided some direct evidence for a genetic
etiology for schizophrenia and direct evidence for genetic
architecture either in linkage studies
14 or association
studies particularly genome-wide studies using both sin-
gle-nucleotide polymorphisms (SNPs) and copy number
variants (CNVs, submicroscopic structural variants in-
cludinginsertionsanddeletions).
15–20Nextgenerationse-
quencing studies are expected to provide evidence for the
relative importance of rare variants.
The Models Rejected Before the Era of GWAS
Although rare variants of large effect size do exist, such as
the translocation that disrupts 2 overlapping brain
expressed genes on chromosome 1 (DISC1 and DISC2)
in a Scottish pedigree,
21 and major chromosomal abnor-
malitiesarepresentinasmallproportionofcases(reviewed
inTandonetal
13),theseareverymuchtheexceptionrather
than the rule,andfewlarge pedigrees have been identified.
Therefore, the simplest genetic architectures were rejected,
recognizingthattheobservedrecurrencerisksandsegrega-
tion patterns within families could not be explained either
byasinglegeneticlocus
22norbymultiplesingleloci.
4They
also could not be explained by models in which risk loci
combinetheireffectsadditivelyonthescaleofrisk.
4Knowl-
edge of family history, differentiating between so-called
sporadic and familial cases, was found not to be useful
inunderstandingtheetiologyofschizophrenia,
23,24andin-
deed,sporadiccasesareexpectedtobethenormincomplex
genetic diseases of low prevalence without invoking new
mutations of large effect.
25 However, beyond these broad
exclusions,anumberofgeneticmodelscouldallexplainthe
observedrecurrencerisks:eitheroligogenicmodelsofafew
risklocieachofrelativelylargeeffectorpolygenicmodelsof
alargenumberoflocieachofsmallereffect.Beforeimpos-
ing the new information generated from GWAS, we will
explore some of these genetic models.
Visualizing a Multiplicative Model
We take over from where Risch
4 left off, that the genetic
architecture of schizophrenia must be represented at least
by a few risk variants that combine in a multiplicative
way on the risk scale in order to generate a pattern of re-
currence risk to relatives similar to that observed. Can we
visualizethismultiplicativemodel?Figure1showssimple
multiplicative models that are approximately consistent
with schizophrenia in that disease prevalence is approx-
imately 0.72% and heritability approximately 0.7. It
shows 3 relationships with number of risk loci on the
x-axis. Firstly, the bell-shaped curve shows the probabil-
ity distribution of individuals in the population having x
risk alleles; for x-axis a), 50 binomially distributed loci
take on a normal distribution about a mean of 2 3 50 3
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150.3 = 30 risk alleles. The S-shaped curve shows the prob-
abilityofdiseaseontheriskscale;forx-axisa)individuals
carrying less than 38 risk loci have probability of disease
closeto0,andforthosewithmorethan43riskloci,disease
is guaranteed. The straight line shows the increase in risk
or probability of disease on the log scale, illustrating that
on this scale the risks of alleles combine additively. Many
combinations of number of risk alleles, risk allele fre-
quency,andeffectsizeareconsistentwiththeobservedre-
currence risks to relatives, illustrated by the alternative x-
axes;allgenerateasteepriseinprobabilityofdiseasewith
increasingnumberofriskalleles,implyingthatthegenetic
architecture must include epistasis on the risk scale.
4
Exchangeable Models
Other genetic models can generate the steep rise in prob-
ability of disease for a small proportion of the popula-
tion. For example, the liability threshold model
6,26–28
assumes that individuals in a population possess an un-
seen liability to disease, and only those whose liability
exceeds a given threshold are affected. The liability has
genetic and environmental component on this notional
liability scale; risk alleles and environmental risks com-
bine additively. But on the risk scale, risk alleles (and en-
vironmental factors) combine with interaction. Figure 2
showstheequivalentrelationshipstothoseinfigure1;the
bell-shaped curve is the frequency distribution of the ge-
netic liability; the straight line shows (of course) that
genetic liability is additive on the liability scale, and
the S-shaped curve shows the probability of disease on
the risk scale (the Probit transformation of the genetic
liabilities). Heritability defines the steepness of the rise
in probability of disease, and the disease prevalence
determines the position of rise along the x-axis relative
to the population distribution of liability. Because the
Table 1. Observed Recurrence Risks to Relatives and Those Predicted Under the Liability Threshold Model
Observed
Predicted Using Liability
Threshold Model
a
Risch
4
Based on
McGue
et al
2
Lichtenstein et al
30
Estimates
95% Conﬁdence
Intervals
Using Prevalence
and Sibling Risk
of Risch
4
Using Prevalence
and Heritability of
Lichtenstein et al
30
Lifetime prevalence (%) 0.85 0.407 0.85
b 0.407
c
Recurrence risks
Parent 9.43 8.26–10.8 8.6 8.6
Offspring 10.0 10.3 8.76–12.2 8.6 8.6
Offspring of 2 affected
parents
89 18.8–672 41 44
Full-sibs 8.6 8.55 7.61–9.60 8.6 8.6
Dizygotic twins 14.2 8.6 8.6
Half-sibs 3.5 2.52 1.56–4.05 3.4 3.3
Nephew/nieces 3.1 2.71 2.22–3.21 3.4 3.3
Grand children 3.3 2.95 1.81–4.81 3.4 3.3
Uncles/aunts 3.2 3.04 2.39–3.87 3.4 3.3
Grand parents 3.8 2.75–5.26 3.4 3.3
First cousin 1.8 2.29 1.71–3.07 1.9 1.9
Monozygotic 52.1 37 38
Proportion of individuals
with affected family members
—
d 3.81
e 3.62–4.00 32
f 17
f
aFrom simulations of 10
6 three generation families. Phenotypes (Y) of liability simulated as Y = A þ E, where A is additive genetic and
E is environmental component. E simulated as E;N(0,1   h
2), where h
2 is heritability of liability. For founders, A;N(0,h
2); for
nonfounders, A=1=2Amum þ 1=2Adad þ Aw; where Aw;N

0;1=2h2
: Individuals are diseased if Y > T, where T truncates the normal
distribution at the proportion defined by the disease prevalence.
bUses a heritability of liability of 0.80 which is consistent with disease prevalence 0.85% and sibling recurrence risk of 8.6
10
cUses a heritability of liability of 0.64 that was estimated from this data.
12
dNo estimate provided in these references, but frequency <33% suggested in review.
13
eCounting all identified first-, second-, and third-degree relatives.
fAssuming nuclear family size of with Poisson mean 2.2 children and complete knowledge of disease status of all first-, second- and
third-degree relatives and assuming no assortative mating and no differences in fertility based on disease status.
25
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N. R. Wray & P. M. Visscherthreshold model produces the same steep rise (implying
epistasis
27) in risk as the multiplicative model, and be-
causethe steep rise is anecessaryrequirement fora model
to generate the observed pattern of recurrence risks, it is
a useful model with which to develop theory. It requires
no explicit assumptions about 3 key features of genetic
architecture, number of loci, risk allele frequencies,
and risk allele effect sizes and is simply parameterized
in terms of the total variance they explain; there is no re-
quirementthatriskvariantsarecommon.Themathemat-
ical development assumes a normal distribution of
liability that is approximately achieved even with a small
number of risk loci, and the model is quite robust to devi-
ations from normality as long as the distribution is unim-
odal.
6 The mathematical tractability of the threshold
model makes it a useful way to summarize genetic archi-
tecturethatappliesequallytoarangeof‘‘exchangeable’’
5
genetic models that may appear to be described differ-
ently but that cannot be differentiated in practice.
Visualizing the Liability Threshold Model
In order to better visualize the liability threshold model,
consider an analogy with height. We are all so familiar
with the variation in human height that we are intuitively
comfortable in recognizing that about 80% of the varia-
tion in height that we observe is of genetic origin (ie, the
heritability is 80%). Adult children of short parents tend
to be shorter than those of tall parents, yet there is var-
iation between the children within families. Indeed, half
of the genetic variation in populations occurs between
families (the variance of the family means), and half
the variation occurs within families,
6 resulting from
the unique set of genetic effects received by each child
from each parent in the meiotic sampling process. Imag-
ine the ‘‘disease’’ of ‘‘loftiness’’ that affects the top 0.72%
of the population. If we lined up the population in height
order, then they would be ranked on their phenotypic li-
ability to loftiness. If the population were ordered on
their genetic liability, then the order would change but
not too much because the heritability is high. Intuitively,
we recognize that relatives of those with loftiness would
also have an increased risk of loftiness. However, we can
also visualize that 0.72% is a small proportion of the pop-
ulation and even families we consider tall might not have
many individuals who pass the threshold into loftiness.
Fig. 2. Visualizing the Genetic Architecture of Complex Genetic
Disease Under a Liability Threshold Model for a Disease With
Frequency 0.72% and Heritability of 0.7. The model is expressed in
terms of the genetic variance and so can represent an infinite
combination of number of loci, risk allele frequencies, and effect
sizes. The black dashed bell-shaped line represents the frequency
distributionofliabilities.Thestraightdot-dashedlinerepresentsthe
additivegeneticactionontheliabilityscale.Thesolidlineshowsthat
on the risk scale the risk alleles combine nonadditively.
Fig. 1. Visualizing a Genetic Architecture Where Risk Alleles Act
Multiplicatively. All examples represent a disease with frequency
0.72% and heritability of ;0.7. Under a simple multiplicative
modelofnrisklocicontributingtodiseaseeachwithrelativeriskR,
theprobabilityofdiseaseinanindividualcarryingxrisklocioutof
the possible 2n is P(Djx) 5 BR
x,, assuming multiplicativity of risk
allelesbothwithinandbetweenloci.B istheprobabilityofdisease
inindividualscarryingnoriskloci,ie,P(Djx50)5BR
05B,withB
defined so that RP(Djx)P(x) 5 disease prevalence. Because B is
verycloseto0,xmustbehighbeforeR
xisbigenoughtoraiseBR
x
frombeingcloseto0.P(Djx)isconstrainedtohaveamaximumof
1. Risch
4 did not recognize the need to impose this constraint that
impactsonhispredictedresults(discussedelsewhere
5).Thedashed
bell-shapedlinerepresentsthefrequencydistributionofriskalleles
P(x), the straight dot-dashed line represents the additive
genetic action on the log(risk) scale, log(P(Djx)) 5 log(BR
x) 5
xlog(BR),andthesolidline representsthemultiplicativeactionof
risk alleles on the risk scale, P(Djx).T h es a m es h a p e so f
distributions are seen for different genetic architectures as shown
by alternative x-axes a)-d).
17
Genetic ArchitectureOur analogy continues by recognizing that liability to
schizophrenia also has a high heritability and that the
prevalence of schizophrenia in the population approxi-
mately 0.72%, but of course we cannot see liability to
schizophrenia, and all we can observe are those individ-
uals who cross the threshold of disease. The epidemiolog-
ical parameters that we can measure (the combination of
disease prevalence and recurrence risks to relatives) fit
with what we would expect under the liability threshold
model(table1),furthersuggestingthatitremainsauseful
model. Under thissimple model, apparentlysporadicdis-
ease is the norm (table 1)
25; our predicted proportion of
affected relatives is higher than that observed in the
Swedish national study, but we assume full knowledge
of true disease status of all relatives regardless of age.
The frequency of sporadic cases was given at least
two-thirds in the recent review of Tandon et al,
13 not in-
consistent with the predictions. The simple modeling
ignores observations of the epidemiology of schizophre-
nia that could impact on genetic variance over genera-
tions: Decreased fertility
29 of diseased individuals
would decrease genetic variance while assortative mat-
ing,
30,31 and mutations accumulating over generations
(including de novo mutations associated with paternal
age
32) would serve to increase genetic variance.
Can GWAS Help Our Understanding of the Genetic
Architecture of Schizophrenia?
Technologicaladvancesallowustomeasuregeneticpoly-
morphisms at several 100 000 locations across the ge-
nome in large cohorts of individuals. GWAS are designed
to identify SNPs or CNVs associated with case-control
status.
33 This has the potential to describe the genetic eti-
ology of complex disease in quite different terms to the
recurrence risks to relatives. In order to understand
how these studies can contribute to an understanding
of genetic architecture, we must recognize what the stud-
ies are designed to detect. The earlier generation of can-
didate gene association studies had led us to ensure that
sample sizes of GWAS were large, allowing detection of
risk alleles of small effect (relative risk > approximately
1.3) despite the unprecedented level of multiple testing.
Nonetheless, there was a hope that our poor selection
of genes in the era of candidate studies underlay the small
number of associated variants that had been detected and
thatcommonvariantsofmoderateeffectsizedidexist.As
an example, we use the International Schizophrenia Con-
sortium (ISC) study
16 that was one of the larger first-
generation GWAS, with 3322 case subjects and 3587
control subjects. The detailed power calculations pro-
vided in that study show that it had 100% power to detect
a risk allele with frequency 0.2 and relative risk 1.5 at the
stringent genome-wide level of significance of 5 3 10
 8
.
The ISC samples were genotyped on either the Affyme-
trix 5.0 or 6.0 chips, so that at least 300 000 SNPs sur-
vived quality control checks on all samples, but
imputation using HapMap samples and the knowledge
of correlations between known SNPs allowed association
analysis of >1.6 million SNPs. Deep sequencing studies
have estimated that the Affymetrix chips tag approxi-
mately 70%–80% of the total genomic variance of
SNPs
34 and the majority of CNVs.
35,36
What GWAS Have not Found
Other reviews
37,38 have focused on the handful of inter-
esting rare and common variants that have been identi-
fied through GWAS
15–20,39–41 including de novo
mutations.
42 In particular, there is mounting evidence
that rare CNVs of moderate effect size play an important
role in schizophrenia (reviewed in O’Donovan et al
43).
However, an equally important result is perhaps not
what GWAS have found but what they have not found.
In the ISC study, not one SNP and only one imputed
SNP reached genome-wide significance. Because there
was 100% power to detect common variants with relative
risk of 1.5 and because a high proportion of the genomic
variance was tagged by the genotyped SNPs, we can im-
mediately narrow down our expectation of the genetic ar-
chitecture of schizophrenia by excluding a model based
onarelativelysmallnumberofcommonvariantsofmod-
erate effect. However,from this first observation,wecan-
not exclude common variants of small effect size or rare
variants of small or moderate effect size (important con-
tributions to genetic variance by rare variants of large
effect size were already excluded—see above). Either
way, we must conclude (from equation 1) that a large
number of variants must underlie the genetic etiology
of schizophrenia. Can GWAS help us go further in nar-
rowing the genetic architecture of schizophrenia?
Standard association analyses are geared to identify as-
sociated loci that are unlikely to be false positives. This is
importantifwearegoingtofollowupidentifiedlociintime-
consumingandcostlyfunctionalstudies.Inthesupplemen-
taryinformationoftheISCstudy,powerwasexploredfrom
adifferentangle.Theexampleofanassociatedvariantwith
relative risk 1.05 and frequency 0.2 was considered. The
power was 0 to detect association of this variant at the ge-
nome-widesignificancetypeIerrorratebecauseitwouldbe
expected to have allele frequency of 0.2079 in case subjects
and 0.1999 in control subjects. Even with 10 000 case sub-
jectsand10 000controlsubjects,powerattherelativelylow
threshold of 1 3 10
 6 was only 0.2%. Yet, these power cal-
culationscanbeturnedontheirheadtorecognizethat46%
ofthetimewewouldexpecttoseevariantsofthissizewithP
valueslessthan0.2,and72%ofthetimetheywillfeaturein
the top half of the list. So if our genotyped SNPs were as-
sociated with low effect size, we might expect to see an en-
richment of small P values. If many weakly associated
variants were detected in an association study, then we
would expect the quantile-quantile (Q-Q) plot of
18
N. R. Wray & P. M. Visschergenome-wideassociationstoriseabovethelineofexpecta-
tion. The Q-Q plot represents the relationship between the
rankedP values obtainedfromtheGWAS andthe ranked
P values expected under the null hypothesis of no associa-
tion.TheQ-QplotfromtheISCstudy(figureS2ofPurcell
etal
16)showsmoresmallp-valuesthanexpectedbychance.
This is typical of Q-Q plots from GWAS of complex traits
(eg, Easton et al
44), but the excess of lowly associated var-
iants mayreflectunknown biasessuchaspopulation strat-
ification or technical artifacts.
Is the Excess of Lowly Associated Variants in GWAS of
Complex Diseases an Artifact or Real?
IntheISCstudy,theanalysisteamsetouttoinvestigateif
the excess of lowly associated variants reflected true pos-
itives, arguing that although we could not distinguish in-
dividual true from false positives, sets of lowly associated
SNPs would be (mildly) predictive of disease status in
other datasets if those sets did indeed contain an excess
of true positives. The basic idea was that by combining
the estimated effect sizes of many SNPs simultaneously
we could detect a genome-wide signature of association.
We used sets of SNPs including all those with P values
less than thresholds of 0.1, 0.2, 0.3, 0.4, and 0.5 identified
fromtheISC study,recognizingthatbychancealone0.1,
0.2, etc, of the SNPs would fall into these categories. For
clarity, we used sets of SNPs in linkage equilibrium, al-
though this restriction had little impact on our results.
For each SNP in a SNP set, we recorded the associated
allele and its odds ratio. For each individual from other
(‘‘target’’)GWAS,wegeneratedascoreregardlessoftheir
case-control status. The score was a weighted sum of the
log(odds) for each associated allele harbored by an indi-
vidual.Logisticregressionofcase-controlstatusonprofile
scorein the target studies providedevidence that the SNP
sets were indeed predictive of case-control status. The
scores only explained 3% of the variance in schizophrenia
case-controlstatus,butthelargesamplesizesensuredthat
thiswas highly significant(up toP = 2 3 10
 28). Doesthis
result unequivocally represent the detection of true com-
moncausalgeneticvariants?IntheISCstudy,theanalysis
team considered carefully whether systematic differences
betweencasesandcontrolsacrossstudysamplescouldex-
plain the results. Population stratification seems an un-
likely confounder because the same population strata
wouldbe neededincases andcontrolsbetweengeograph-
ically diverse samples. However, unknown technical arti-
facts such as consistent differences across studies in
storageconditionsofclinicalcasesvspopulationsampled
controls may still prevail. Stronger confirmation that the
result could not be explained away came from using the
Wellcome Trust Case Control Consortium studies of 7
complex genetic diseases as target study samples; criti-
cally, the same control sample was compared with each
disease sample. For the target samples of coronary artery
disease, Crohn’s disease, hypertension, rheumatoid ar-
thritis, type I diabetes, and type II diabetes, the ISC-iden-
tified SNP sets were not predictive of case-control status
(P > .05), but for bipolar disorder, the scores explained
approximately 2% of the variance in case-control status
atP=1 310
 12,addingtothegrowingliteraturethatsup-
portsasharedgeneticetiologyofschizophreniaandbipo-
lar disorder.
12,38,40 The unequivocal conclusion is that
current generation genome-wide SNP chips do tag some
of the causal genetic variation for schizophrenia. Could
these results provide any further insight into the genetic
architecture of schizophrenia?
Using GWAS to Generate Hypotheses About the Genetic
Architecture of Schizophrenia
As part of the ISC study, the ISC analysis team used sim-
ulationtoexplorewhatgeneticarchitecturescouldexplain
the pattern of results we saw. The simulations used the
samesamplesizeandSNPsasintherealdata.Theparam-
etersvariedwere(i)theproportionofgenotypedSNPsthat
taggedassociatedcausalvariants,(ii)themeaneffectsizeof
thecausalvariants,(iii)thedistributionoftheeffectsizeof
thecausalvariants,and(iv)thelinkagedisequilibriumbe-
tween the genotyped and causal variants. The simulated
data were analyzed in the same way as the real data and
combinations of parameters that generated the same pat-
ternofvarianceexplainedusingdifferentthresholdsforthe
SNPsetsusedin thetarget sampleswere identified. Many
combinations of the parameters could be rejected, but
equally many combinations were consistent with the ob-
served results. As found in early studies relating genetic
modelstorecurrencerisks,andasexpectedfromequation
1,thedrivingforcewasthetotalvarianceexplainedbythe
associatedloci;manycombinationsofnumberofloci,fre-
quencyofassociatedloci,andeffectsizeofassociatedloci
generatethesamevarianceexplained.Butthesimulations
did allow some models to be excluded and togenerate hy-
pothesesthatcanbetestedassamplesizes,andgenotyping
density increase.
The simulations allowed the exclusion of models where
the number of associated variants is less than approxi-
mately100.Inthese situations,the effectsizesofthe asso-
ciated variants needed to be large in order to generate
aprofile that explained 3% ofthe variance in case-control
status.Butiftheeffectsizeswerelarge,thentheywereeasily
detected with low association P values. This meant that
a SNP set defined by a stringent P value threshold ex-
plained a high proportion of the variance in case-control
status,andaddingadditionalSNPsatlessstringentthresh-
oldssimplyaddednoise;thisdidnotfitwithobservations.
The simulations also allowed the exclusion of models
of only rare variants. Acknowledging that the current
generation of genome-wide chips overrepresent common
SNPs, a genetic architecture of ungenotyped rare causal
variants whose effects could only be detected through
19
Genetic Architecturelinkage disequilibrium with genotyped SNPs was investi-
gated. Models with only rare variants of very large effect
could not generate the pattern of variance explained in
case-control status observed with decreasingly stringent
SNP sets. A model with only rare variants of moderate
effect could generate this pattern, but in this case, the
contribution that alleles of different frequencies made
to the variance explained did not match the observed
results. Simulation of rare variants only showed that
SNPs withlowallele frequencywouldbeexpectedtocon-
tribute more to the variance explained in case controls
status than was observed. This is because the linkage dis-
equilibrium (r
2) will be higher for SNPs whose minor
alleles are coupled to the rare variant,
45 and so they
are more likely to generate smaller P values in an asso-
ciation test. A model of only rare variants, with multiple
rare variants present on common haplotype back-
grounds, also could not explain the results.
Consistent with equation 1, the ISC simulations
showedthatwecouldnotdistinguishbetweenasmallpro-
portion of the genotyped variants having small effect size
and all genotyped variants having a very small effect size
and therefore the multitude of combinations in between.
However,the consistent combinations all pointedtoage-
netic variance of liability of 32%–36% tagged by the gen-
otypedSNPs.Thesimulationshavegeneratedhypotheses
that will become testable in a relatively short time frame.
1. As sample size increases, using the same genotyped
SNPs, the proportion of variance in case-control sta-
tus explained will increase but will still reflect the same
32%–36% of variance in liability.
2. As sample size increases, the pattern of variance
explained in case-control status by SNP sets defined
by the stringency of P values will change (because
there is more power to detect variants of small effect
and they will filter toward the top of the P value list).
The change in pattern may allow us to exclude addi-
tional genetic architectures (see figure S8 in Purcell
et al
16) and may shed more light on the relative con-
tributions of rare and common variants.
3. The next generation of SNP chips represents more of
the common genomic variance and would be expected
to explain a higher proportion of the liability variance.
But perhaps the proportion of variance explained will
not be much higher because it is likely that a propor-
tion of the liability variance detectable through recur-
rence risk maynever be detectable throughassociation
or sequencing if there are many rare causal variants of
very small effect.
Visualizing a Polygenic Model
The results from GWAS point strongly to a genetic ar-
chitecture of many (poly) genetic variants. They also im-
ply that both common
15,16,18 and rare variants
17,41 of
small effect contribute to the genetic architecture of
schizophrenia. Only time will tell the genetic architecture
of the unaccounted variance. Evolutionary genetics leads
us to expect an L-shaped
46(or U shaped
47 with pleiot-
ropy)distribution of risk allele frequencies and aninverse
correlation between risk allele frequency and effect size.
46
From equation 1, we expect that, individually, rare var-
iants will contribute only a very small part of the overall
genetic variance. Their overall contribution to the vari-
ance depends on how many there are.
A polygenic model is not inconsistent with the pheno-
typic heterogeneity that characterizes schizophrenia be-
cause each individual will carry their own unique
portfolio of risk alleles that may generate a spectrum of
phenotypes and phenotypic heterogeneity. For example,
forsimplicity,letusassumethatthereare1000geneticvar-
iantscontributingtoriskofdiseaseeachwithfrequency0.1
(figure1,x-axisd).Frombinomialtheory,allindividualsin
thepopulationcarryatleast150riskalleles,anaveragein-
dividual carries 200 risk alleles, and when disease preva-
lence is approximately 0.72% and heritability
approximately 0.7, most of those with disease carry 230–
250riskalleles.Eachwillcarryadifferentsetofriskalleles
out of the maximum of 2000 (2 per locus).
One consequence of there being many risk variants is
that the impact of a given risk variant depends on the ge-
netic (and environmental) background of an individual.
In our simplified example, there is no noticeable differ-
ence in probability of disease for individuals with 200
or 201 risk loci, yet there is a difference between individ-
ualswith240or241riskloci(figure1x-axisd).Thismeans
that risk variants detected with a small genotype relative
risk can still be biologically very important. Therefore,
identified truly associated common variants are worthy
of functional investigation even if their estimated effect
sizes are very small.
We have shown that the constraints of low disease
prevalence and high heritability imply a steep increase
in probability with disease for individuals with a high
burden of risk alleles. Therefore, a normal phenotype
is maintained when individuals harbor a manageable
number of risk variants. This implies that biological sys-
tems can compensate for minor deviations from the nor-
mal equilibrium, eg, through alternate pathways, so that
the disease phenotype is only revealed when the system
cannot compensate for a large number of perturbations.
This further implies a considerable degree of redundancy
of genetic material that is completely consistent with
a range of studies, eg, knocking out an entire gene of
known function often has no or unexpected impact on
the phenotype,
48–51 and protein interaction studies
haveshownthat thevast majorityofknowndiseasegenes
are individually nonessential.
52 This robustness allows
accumulation of mutations.
53 Moreover, while theories
of balancing selection argue against common variants
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N. R. Wray & P. M. Visscherof large effect but not against many common variants of
small effect.
54Indeed, ifeachcomplex geneticdisease and
trait is underpinned by thousands of genetic variants,
models of multiple pleiotropy of each risk variant
55 are
necessarilyinferred(ie,avariantthathasanegativeeffect
on some characteristics may have a positive effective on
others). Multiple pleiotropy is a mechanism to maintain
geneticvariance
47,56becausethecontributiontofitnessof
a risk allele reflects its average contribution across its
pleiotropic functions.
Prediction of Genetic Risk
Genetic variants that confer only a small increase risk to
diseaseareindividuallynotusefulinpredictingaperson’s
genetic risk to disease. However, a risk equation combin-
ingpresence/absenceofeachriskvariantanditseffectsize
can generate a personalizedprediction ofgenetic risk. We
investigated this problem using simulation of GWAS.
57
Oursimulationsshowedthat onlywhenGWAS comprise
about 10 000 cases and controls, would it be possible for
a useful proportion of variance in disease status to be
explained, even though the risks conveyed by individual
variants are small. If associated variants explain half of
the known genetic variance in liability of schizophrenia,
then a multilocus genetic risk profile would generate an
area under the receiver operator characteristic curve
(a well-established tool for determining the efficacy of
clinical diagnostic and prognostic tests in correctly clas-
sifying diseased and nondiseased individuals) of approx-
imately0.9(N.R.W.,J.Yang,PhD,M.E.Goddard,PhD,
P.M.V., 2009 unpublished data,).
Prediction of genetic risk is perhaps likely to generate
t h em o s ti m m e d i a t ei m p a c to ft h er e s u l t so fG W A Si n
the clinical setting. This is because in prediction of ge-
neticrisk,theassociatedSNPs(orothermarkers)donot
have to be the causative mutations: They just need to be
correlated with the causative mutations ensuring that
there is a consistent association between the variants
used in prediction and disease risk. Ethical considera-
tions
58 govern the use of genetic risk prediction, but
to some extent these issues have been bypassed through
the availabilityof direct to consumer testing (necessarily
with very limited efficacy at this point). Despite ethical
concerns,predictionofgeneticriskmaybean important
toolforidentifyingschizophreniainitsprodromalphase
thatisthekeytoearlyintervention.
59Aroundtheworld,
protocols have been developed for identification of
patients at ultrahigh risk of developing psychosis
60 that
includes genetic risk through family history; but, as we
have shown, a very high proportion of schizophrenia
casesubjectswillhavenocloserelativeswiththedisorder.
Moreover, as half the genetic variance occurs within
families,
6 each child of a parent with schizophrenia will
haveadifferentgeneticriskfordiseaseeventhoughtheir
risk based on family history is the same. Individuals
whose genetic risk coincides with the steep rise in
probabilityofdisease(figures1and2)arethosemostvul-
nerabletoenvironmentalriskfactorssuchasrecreational
drug use.
Conclusion
Early studies showed that many different genetic archi-
tecturescouldexplaintheobservedrecurrencerisksinrel-
atives of schizophrenics. However, those studies were
able to exclude the most simple genetic models and con-
cluded that each individual with schizophrenia harbored
at least ‘‘a few’’ genetic risk variants that act multiplica-
tively.
4 Recent GWAS have allowed us to exclude addi-
tional genetic architectures, showing that a genetic
architecture of less than 100 risk variants and a genetic
architecture of only rare variants are both not consistent
with observed data. The GWAS provide evidence that
perhaps half of the known genetic variance is tagged
by common variants some of which is directly attribut-
able to common causal variants of small effect. As
GWAS sample sizes increase and as genotyping chips ac-
count for more of the genomic variance, the genetic ar-
chitecture will become clearer. Genetic theory expects us
to anticipate that some of the genetic variance so far not
accounted for will be explained by rare variants, even
though individually the contribution of each variant
will be very small. We would expect the spectrum to in-
clude rare variants of small effect, which may never be
identified. Several genetic models that represent the
way in which risk variants combine to contribute to
risk of disease can all explain observed results, and it
is unlikely that we will be able to differentiate between
them. All models require epistasis on the risk scale, which
is essential to produce the steep rise in probability of dis-
ease necessary to generate the pattern of observed recur-
rence risks to relatives. The most tangible and immediate
outcome of the GWAS may be prediction of genetic risk
to disease, which may be an important tool in ensuring
early intervention treatments.
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